Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Telik
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Primary or de Novo MDS
Low to Intermediate-1 IPSS risk of MDS
ECOG performance score of 0 or 1
Documentation of significant anemia with or without additional cytopenia
Adequate kidney and liver function
Patients must have discontinued hematopoietic growth factors at least 3 weeks prior to study entry
You may not be if
Deletion of the 5q chromosome \[del(5q) MDS\]
Prior allogenic bone marrow transplant for MDS
Known sensitivity to ezatiostat (injection or oral tablets)
Prior treatment with hypomethylating agent (HMA) (e.g., azacitadine, decitabine)
History of MDS IPSS risk score of greater than 1.0
Pregnant or lactating women
Any severe concurrent disease, infection or comorbidity that, in the judgement of the investigator, would make the patient inappropriate for study entry
Oral steroids greater than 10 mg per day. Exceptions: those prescribed for other conditions (such as new adrenal failure, asthma, arthritis) or brief sterioid use (such as tapered dosing for an acute non-MDS condition)
History of hepatitis B or C, or HIV
Clareo Health | Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
